GH secretagogues and uses thereof
The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
1. A method of treating HIV-related lipodystrophy in a subject without significantly impairing glucose control,
said method comprising administering to said subject (hexenoyl trans-3)hGRF(1-44)NH 2 (SEQ ID NO: 7) to treat said HIV-related lipodystrophy without significantly impairing glucose control.
2. The method of claim 1 , wherein said subject is receiving antiviral therapy.
3. The method of claim 1 , wherein said (hexenoyl trans-3)hGRF(1-44)NH 2 (SEQ ID NO: 7) is administered at a dose selected from the group consisting of about 1 mg and about 2 mg.
4. The method of claim 1 , wherein said (hexenoyl trans-3)hGRF(1-44)NH 2 (SEQ ID NO: 7) is administered by a route selected from the group consisting of intravenous, oral, transdermal, subcutaneous, mucosal, intramuscular, intranasal, intrapulmonary, parenteral, intrarectal and topical.
5. The method of claim 4 , wherein said (hexenoyl trans-3)hGRF(1-44)NH 2 (SEQ ID NO: 7) is administered by a subcutaneous route.
6. The method of claim 3 , wherein said (hexenoyl trans-3)hGRF(1-44)NH 2 (SEQ ID NO: 7) is administered at a dose of about 2 mg.
7. The method of claim 5 , wherein said (hexenoyl trans-3)hGRF(1-44)NH 2 (SEQ ID NO: 7) is administered at a dose selected from the group consisting of about 1 mg and about 2 mg.
8. The method of claim 7 , wherein said (hexenoyl trans-3)hGRF(1-44)NH 2 (SEQ ID NO: 7) is administered at a dose of about 2 mg.
9. The method of claim 1 , wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation.
10. The method of claim 2 , wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation.
11. The method of claim 3 , wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation.
12. The method of claim 4 , wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation.
13. The method of claim 5 , wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation.
14. The method of claim 6 , wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation.
15. The method of claim 7 , wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation.
16. The method of claim 8 , wherein said treating HIV-related lipodystrophy comprises treating visceral fat accumulation.
17. The method of claim 1 , wherein said subject further suffers from type II diabetes or glucose intolerance.
18. The method of claim 2 , wherein said subject further suffers from type II diabetes or glucose intolerance.
19. The method of claim 3 , wherein said subject further suffers from type II diabetes or glucose intolerance.
20. The method of claim 4 , wherein said subject further suffers from type II diabetes or glucose intolerance.
21. The method of claim 5 , wherein said subject further suffers from type II diabetes or glucose intolerance.
22. The method of claim 6 , wherein said subject further suffers from type II diabetes or glucose intolerance.
23. The method of claim 7 , wherein said subject further suffers from type II diabetes or glucose intolerance.
24. The method of claim 8 , wherein said subject further suffers from type II diabetes or glucose intolerance.
25. The method of claim 9 , wherein said subject further suffers from type II diabetes or glucose intolerance.